Lupin

Lupin’s subsidiary, MedQuimica acquires rights to nine brands from Bausch Health

Read more

Lupin announces Q2 FY2023 results

Read more

Lupin gets FDA nod to market generic antibiotic medicine in US

Read more

US FDA issues warning letter to Lupin for Maharashtra-based API plant

Read more

Lupin signs agreement to acquire two inhalation brands from Sunovion

Read more

Lupin to acquire two inhalation brands from Sunovion for $75 million

Read more

Lupin partners with global agencies to increase patient access to TB prevention treatment

Read more

Lupin appoints Dr Shahin Fesharaki as Global Chief Scientific Officer

Read more

US FDA grants EIR to Lupin’s Ankleshwar manufacturing facility

Read more

US FDA approves Lupin’s Mirabegron extended-release tablets

Read more